articleTop 1% cited

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Journal of Clinical Oncology · 2009 · Vol. 27(28) · pp. 4656–4663

Anja Rinke✉(Universität Hamburg)Hans‐Helge Müller(Universität Hamburg)Carmen Schade‐Brittinger(Universität Hamburg)Klaus‐Jochen Klose(Universität Hamburg)Peter Barth(Universität Hamburg)M. Wied(Universität Hamburg)Christina Mayer(Universität Hamburg)Behnaz Aminossadati(Universität Hamburg)Ulrich‐Frank Pape(Universität Hamburg)Michael Bläker(Universität Hamburg)Jan Harder(Universität Hamburg)Christian Arnold(Universität Hamburg)Thomas M. Gress(Universität Hamburg)Rudolf Arnold(Universität Hamburg)

View via DOI Publisher page

Abstract

Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory.

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Neuroblastoma Research and TreatmentsMedicineOctreotidePlaceboNeuroendocrine tumorsInterim analysisInternal medicineTumor progressionGastroenterologySomatostatinHazard ratio

MeSH terms

DiarrheaDouble-Blind MethodFemaleHumansIntestinal NeoplasmsLiver NeoplasmsMalePlacebosPrognosisProspective StudiesQuality of LifeOctreotideAbdominal PainSurvival AnalysisTreatment Outcome

Citations

2,474

FWCI

81.36

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours